{"protocolSection":{"identificationModule":{"nctId":"NCT05240560","orgStudyIdInfo":{"id":"P20-04 / BP1.3656"},"secondaryIdInfos":[{"id":"2020-006006-23","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Bioprojet","class":"OTHER"},"briefTitle":"Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke","officialTitle":"A Multisite Randomized Clinical Trial Evaluating Efficacy and Safety of BP1.3656 vs Placebo in Patients With Fatigue Following Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-01-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-01-20","studyFirstSubmitQcDate":"2022-02-14","studyFirstPostDateStruct":{"date":"2022-02-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-13","lastUpdatePostDateStruct":{"date":"2023-06-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bioprojet","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Multicenter, randomized, double blind, parallel-group, placebo-controlled proof of concept study evaluating efficacy and safety of BP1.3656 in patients with fatigue following ischemic stroke."},"conditionsModule":{"conditions":["Fatigue"],"keywords":["Post-stroke fatigue"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"The placebo tablets will be identical in appearance to the BP1.3656 tablets.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":54,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"BP1.3656","type":"EXPERIMENTAL","description":"1 tablet of 30 microgram (µg), 60µg or 90µg of BP1.3656 per day","interventionNames":["Drug: BP1.3656"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"1 tablet of matching placebo per day","interventionNames":["Drug: BP1.3656"]}],"interventions":[{"type":"DRUG","name":"BP1.3656","description":"Histamine H3 receptor antagonist/inverse agonist","armGroupLabels":["BP1.3656","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Multidimensional Fatigue Inventory (MFI-20) global score","description":"20-item self-report instrument designed to measure fatigue experienced by the participant lately scored from 20 to 100. Higher scores show higher levels of fatigue.","timeFrame":"Week 8"}],"otherOutcomes":[{"measure":"Incidence of Treatment-Emergent Adverse Events (AEs) as assessed by AEs collection","description":"Safety assessment of BP1.3656 based on adverse events (AEs) reporting during treatment period.","timeFrame":"Week 8"},{"measure":"Change in Systolic blood pressure (BP) measurement","description":"Safety assessment of BP1.3656 based on the measurement of systolic blood pressure in units of millimeters of mercury (mmHg)","timeFrame":"From baseline to Week 8"},{"measure":"Change in Diastolic blood pressure (BP) measurement","description":"Safety assessment of BP1.3656 based on the measurement of Diastolic blood pressure in units of millimeters of mercury (mmHg)","timeFrame":"From baseline to Week 8"},{"measure":"Change in pulse","description":"Safety assessment of BP1.3656 based on the measurement of pulse in beats/minute","timeFrame":"From baseline to Week 8"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females 18 years old or more;\n* Diagnosis of ischemic stroke at least one month and not more than six months prior to screening;\n* Persistent fatigue since the stroke with a score ≥ 60 across all domains of the Multidimensional Fatigue Inventory (MFI-20);\n* Modified Rankin Score (mRS) \\< 3;\n* Capability to participate in all study tests according to the investigator;\n* Patient must voluntarily express a willingness to participate in this study, sign and date an informed consent prior to any study specific procedure;\n* Females of child-bearing potential must have a negative pregnancy test performed at the screening and randomization visits and use a medically accepted effective method of birth control, agree to continue this method for the duration of the study up until three weeks after last treatment intake.\n\nExclusion Criteria:\n\n* Any identified etiology for fatigue other than stroke according to the investigator;\n* History of psychosis;\n* Current severe psychiatric disorder, e.g. schizophrenia, bipolar disorder, severe depression, or organic brain syndrome preventing the patients from completing study assessments;\n* Patients at risk of suicide according to the investigator;\n* Major cognitive disorders, dementia according to the investigator;\n* History of epilepsy or seizures disorder;\n* History of alcohol or drugs (i.e. cannabis, cocaine, amphetamines or opioids) (ab)use/dependence within the 12 months prior to screening or with a positive drug test at screening;\n* Glomerular filtration rate \\<60 mL/min/1.73m² according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula;\n* Clinically significant cardiovascular abnormalities (including clinically relevant ECG abnormalities) or, clinically significant hematological, neurological, endocrine abnormalities, severe hepatic impairment or Liver Function Tests (ASAT, ALAT) \\> 3 ULN, or abnormal clinical laboratory results (in most cases \\> 3ULN);\n* Other active clinically significant illness, infection, acid-related gastric disorder, or neoplastic pathology within the last 3 years (patients with fully cured non-melanoma skin cancer or in-situ carcinoma of the cervix are eligible) which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise his/her study participation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Stéphanie Renaux","role":"CONTACT","phone":"+33147036633","email":"s.renaux@bioprojet.com"},{"name":"Martine Le Gall","role":"CONTACT","phone":"+33147036633","email":"m.legall@bioprojet.com"}],"overallOfficials":[{"name":"Claudio Bassetti, MD, Prof.","affiliation":"Inselspital Bern, Department of Neurology, Bern, Switzerland","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Hôpital Pellegrin - CHU BORDEAUX","status":"RECRUITING","city":"Bordeaux","zip":"33076","country":"France","contacts":[{"name":"Coordinator France/Site principal investigator","role":"CONTACT"}],"geoPoint":{"lat":44.84044,"lon":-0.5805}},{"facility":"Inselspital Berne","status":"NOT_YET_RECRUITING","city":"Berne","zip":"3010","country":"Switzerland","contacts":[{"name":"Site principal investigator","role":"CONTACT"}],"geoPoint":{"lat":46.94809,"lon":7.44744}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000005221","term":"Fatigue"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M8054","name":"Fatigue","asFound":"Fatigue","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M9398","name":"Histamine","relevance":"LOW"},{"id":"M212106","name":"Histamine phosphate","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}